Apellis says ‘no indication’ vision drug has led to eye inflammation (NASDAQ:APLS)

Apellis says ‘no indication’ vision drug has led to eye inflammation (NASDAQ:APLS)

Apellis says 'no indication' vision drug has led to eye inflammation

Source link